Medipost Reports Positive Phase 3 Results for CARTISTEM in Japan’s Knee Osteoarthritis Trial_蜘蛛资讯网
스1) 문대현 기자 = Medipost announced on Wednesday that its umbilical cord-derived allogeneic mesenchymal stem cell therapy, CARTISTEM®, has successfully met all primary and secondary efficacy endpoints in
ed the control group in both secondary evaluation indicators: improvements in knee pain and function (Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores), and the rate of ICRS Gr